Home Cart Sign in  
Chemical Structure| 496054-87-6 Chemical Structure| 496054-87-6

Structure of Radiprodil
CAS No.: 496054-87-6

Chemical Structure| 496054-87-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Radiprodil is a selective antagonist of NMDA NR2B that used in treatment of neuropathic pain.

Synonyms: RGH-896

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Radiprodil

CAS No. :496054-87-6
Formula : C21H20FN3O4
M.W : 397.40
SMILES Code : O=C(NC1=CC=C2NC(OC2=C1)=O)C(N3CCC(CC4=CC=C(F)C=C4)CC3)=O
Synonyms :
RGH-896
MDL No. :MFCD11040157
InChI Key :GKGRZLGAQZPEHO-UHFFFAOYSA-N
Pubchem ID :10200813

Safety of Radiprodil

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P260-P264-P273-P301+P312-P305+P351+P338-P314
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
Radiprodil (RGH-896) is an orally active, selective NMDA NR2B antagonist, identified as a potential treatment for neuropathic pain and possibly other chronic pain conditions[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02829827 Infantile Spasms (IS) PHASE2 TERMINATED 2018-10-02 Ep0078 401, Paris, France
NCT05818943 GRIN-related Disorders PHASE1 ACTIVE_NOT_RECRUITING 2025-11-26 Mid-Atlantic Epilepsy and Slee... More >>p Center, Bethesda, Maryland, 20817, United States|Columbia University Irving Medical Center, Dept of Neurology, New York, New York, 10032, United States|Queensland Children's Hospital, South Brisbane, Queensland, 4101, Australia|The Hospital for Sick Children (Sick Kids), Toronto, Ontario, M5G 1X8, Canada|BC Children's Hospital, Vancouver, BC V6H 3N1, Canada|Abteilung für Neurop?diatrie, Klinik und Poliklinik für Kinder - und Jugendmedizin, Universit?tsklinikum Leipzig, Leipzig, 04103, Germany|KBO-Kinderzentrum München gemeinnützige GmbH, München, 81377, Germany|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu, Roma, Lazio, 00165, Italy|Azienda Ospedaliero Universitaria Careggi (AOUC) Firenze - Azienda Ospedaliera Universitaria Meyer, Firenze, Toscana, 50139, Italy|ERASMUS Medisch Centrum, Developmental & Genetic pediatrics, Rotterdam, 3015, Netherlands|UMC Utrecht - Wilhelmina Kinderziekenhuis, Polikliniek Kinderneurologie, Utrecht, 3508, Netherlands|Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB), Barcelona, 08950, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|Royal Hospital for Children Glasgow, Glasgow, G51 4TF, United Kingdom|Great Ormond Street Hospital For Children NHS Foundation Trust, London, WC1N 3JH, United Kingdom Less <<
NCT06392009 Tuberous Sclerosis Complex|Foc... More >>al Cortical Dysplasia Less << PHASE1|PHASE2 RECRUITING 2025-07-26 Queensland Children Hospital, ... More >>South Brisbane, 4101, Australia|Universitair Ziekenhuis Antwerpen (UZA), Antwerp, 2650, Belgium|University Hospitals Leuven, Pediatric Neurology, Leuven, 3000, Belgium|Alberta Children's Hospital, Calgary, T3A 2X6, Canada|The Hospital for Sick Children (Sick Kids), Toronto, M5G 1X8, Canada|BC Children's Hospital, Vancouver, BC V6H 3N1, Canada|IRCCS Istituto Giannina Gaslini, Genoa, Liguria, 16146, Italy|AOU Meyer, Florence, Toscana, 50139, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, 00165, Italy|Universita Cattolica del Sacro Cuore - Policlinico Universitario "Agostino Gemelli", Roma, 00168, Italy|UMC Uthrecht - Wilhelmina Kinderziekenhuis, Utrecht, 3508, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdańsk, 80952, Poland|Centrum Medyczne Plejady, Kraków, 30363, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, 60356, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka, Warszawa, 04730, Poland|Hospital Universitario Vall D′Hebrón, Barcelona, 08035, Spain|Hospital Materno Infantil Sant Joan de Deu de Barcelona, Barcelona, 08950, Spain|Hospital Universitario Vithas La Milagrosa, Madrid, 28010, Spain|Hospital Ruber Internacional, Madrid, 28034, Spain|University Hospitals Bristol and Weston NHS Foundation Trust Bristol Royal Hospital for Children, Bristol, BS2 8BJ, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.58mL

2.52mL

1.26mL

25.16mL

5.03mL

2.52mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories